^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    laventatug tivedotin (BRY812)

    i
    Other names: BRY812, BRY-812, BRY 812
    Company:
    Zhejiang Hisun
    Drug class:
    Microtubule inhibitor, LIV-1-targeted antibody-drug conjugate
    Related drugs:
    13d
    A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=164, Recruiting, BioRay Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    laventatug tivedotin (BRY812)
    6ms
    Investigation of the cytotoxic effects and mechanisms of the SLC39A6-targeting ADC drug BRY812 in CRC. (PubMed, Sci Rep)
    This study has identified SLC39A6 as a potential therapeutic target in CRC. BRY812 is expected to become a highly promising therapeutic drug, bringing new hope to patients with CRC.
    Journal
    |
    SLC39A6 (Solute Carrier Family 39 Member 6)
    |
    laventatug tivedotin (BRY812)